Sodium-glucose cotransporter 2 (SGLT2) inhibitors are newly developed antihyperglycemic
medications. In addition to their glucose lowering properties, they have been shown to have
favourable effects on the cardiovascular and renal outcome in patients with diabetes. one of
the most interesting renal effects is reduction of proteinuria. The aim of our study was
examine the effect of SGLT inhibitors on proteinuria in patients with glomerulonephritis.
This study is a randomised controlled trial.